ANN ARBOR – Aastrom Biosciences on Tuesday announced the appointment of James Cour as President and Chief Operating Officer, a new position that reports to CEO R. Douglas Armstrong.
“The creation of the position of Chief Operating Officer was based on the continuing growth and progress of the Company on an international level,” Armstrong said. “As we move forward in the execution of value milestones, such as the expansion of our clinical trials and preparations for our commercial operations, the benefit of having additional senior management talent and operational expertise has become evident. Mr. Cour’s operational and business development capabilities will be of tremendous value to Aastrom, and will help the Company continue to meet its goals.”
Cour held executive level management positions with several companies, including Baxter International, Windsor VanGelder Limited and Cytomedix. His skills include development of medical products, biologic pharmaceuticals, business development, strategic alliances, analysis of new technologies, and licensing.
Cour received a Bachelor of Business Administration, with honors, from the University of Notre Dame in 1981, and an MBA from the University of Chicago in 1986, with concentrations in Marketing and International Business, with a specialization in Finance. He was also licensed as a Certified Public Accountant in 1982.
Aastrom is developing proprietary stem cell-based products for the regenerative repair of damaged human tissues and other medical disorders.
